We will include healthy people not suffering from any diseases. We will exclude minors (less than 18 years old), pregnant women, those planning a pregnancy, and lactating women.
Conditions
Interventions
None listed
Sponsors
KAGOME CO., LTD.
Review Team Professor Hiroharu Kamioka, Department of Ecological Symbiotic Science, Tokyo University of Agriculture Ms. Mari Makishi, NARASHINO Media Center for Research &
Education, Media Net Center, TOHO University. Mr. Yudai Aoki, Innovation Division, KAGOME CO., LTD. Ms. Kei Mukuta, Innovation Division, KAGOME CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Study design) We will include randomized controlled parallel trials (RCT-P), randomized controlled crossover trials (RCT-C), quasi randomized controlled parallel trials (qRCT-P), quasi randomized controlled crossover trials (qRCT-C), non-randomized controlled parallel trials (nonRCT-P), non-randomized controlled crossover trials (nonRCT-C), and non-randomized controlled trials. We will include scientific papers and reports which give us enough research details. (PICO) Participant: We will include healthy people not suffering from any diseases. We will exclude minors (less than 18 years old), pregnant women, those planning a pregnancy, and lactating women. Intervention: We define oral intake of Bifidobacterium animalis subsp. lactis BB-12 or the same strain as BB-12 for more than two weeks as an intervention. Comparison: We define oral intake of test food not containing Bifidobacterium animalis subsp. lactis BB-12 and the same strain as BB-12, as controls. We also define maintaining daily life as a control. Outcome measurement: We will evaluate bowel movement frequency as primary outcome. We will evaluate the following markers in stool sample as secondary outcomes: the occupancy of Bifidobacterium genus, the number of Bifidobacterium genus, the number of Lactobacillus group, and the number of lecithinase-positive Clostridium (Clostridim perfringens). (Language) Eligibility is not restricted by language.
Exclusion criteria
Exclusion criteria: We will exclude proceedings and unpublished studies which don't give us enough research details.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will evaluate the effect of Bifidobacterium animalis subsp. lactis BB-12 intake on bowel movement frequency. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will evaluate of the effects of Bifidobacterium animalis subsp. lactis BB-12 intake on the following markers in stool sample: the occupancy of Bifidobacterium genus, the number of Bifidobacterium genus, the number of Lactobacillus group, and the number of lecithinase-positive Clostridium (Clostridim perfringens). | — |
Countries
Japan
Contacts
Public ContactTakuro Inoue
KAGOME CO., LTD. Innovation Division
Outcome results
None listed